Give us a call
Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.
General Enquiries
CSL Limited Head Office
Phone: +61 3 9389 1911
Fax: +61 3 9389 1434
Customer Service
Within Australia
Outside Australia
Media Enquiries
Australian Media Contact
Jimmy Baker
Senior Communications Business Partner
Strategic Communications, Media & Investor Relations
CSL Limited
Mobile: +61 0450 909 211
Country Contacts
CSL Behring
Seqirus
Investors
Computershare
The CSL share registry is managed and maintained by Computershare.
Phone: 1800 646 882
Outside Australia: +61 3 9415 4178
Fax: +61 3 9473 2500
Website: www.investorcentre.com
Medical Information
Undesirable Effect Within Australia
CSL Behring Pharmaceuticals
Phone: 1800 642 865 (Toll Free within Australia)
Undesirable Effect Within New Zealand
Undesirable Effect Outside Australia & New Zealand
CSL Behring
Seqirus
About Seqirus
Seqirus is the world’s No. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe and Australia.
About CSL Behring
We are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of therapies for people with deficient or malfunctioning blood proteins that cause diseases like bleeding disorders, primary immune deficiencies and Alpha 1 proteinase inhibitor deficiencies.